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Abstract
We reviewed the COVID-19 vaccines that reached phase III of clinical development. For each of the 10 vaccines identified, we
described the technology used for vaccine development, the available data from phase III clinical trials, data on vaccine safety,
and the role of new SARS-CoV-2 variants on vaccine efficacy.

Introduction

Vaccine technology

There are exceptional ongoing efforts to develop effective vaccines against SARS-CoV-2 with the goal to control the current COVID-19 pandemic. According to the
World Health organization, as of March 1, 2021, there
are 182 vaccines in preclinical development and 74 vaccines in different phases of clinical development.[1]
We performed a literature review with the objective to
evaluate the vaccine efficacy, safety and technology of
the COVID-19 vaccines that have reached phase III of
clinical development.

For each of the vaccines that reached phase III clinical
trials, the technology used for the development of the
vaccine was identified. These technologies fall into two
categories: protein-based vaccines, used to inject participants with SARS-CoV-2 proteins; and gene-based
vaccines, used to inject participants with SARS-CoV-2
genetic material.

Methods
Vaccines that reached phase III of clinical development
COVID-19 vaccines that had reached phase III of clinical development were identified. These vaccines were
classified in two groups: the vaccines that completed
phase III studies (no longer recruiting participants),
and the vaccines in ongoing phase III studies (still recruiting participants). These groups were further classified according to the quality of the data currently
available to review the efficacy and safety of each vaccine. Priority was given to data obtained from studies
published in peer-reviewed journals, followed by data
obtained from press release documents.

Vaccine phase III clinical trial data
The data from phase III clinical trials were summarized
for vaccines with data available from peer-reviewed
publications and vaccines with only press-released
data. The vaccines were ordered according to the number of COVID-19 cases used to calculate their efficacy,
prioritizing studies with a greater number of COVID19 cases. We also evaluated the generalizability of their
respective study data, as determined by the number of
study subjects and the number of countries participating in the trial.
Vaccine safety data
Data concerning the safety of the vaccines were obtained from peer-reviewed publications as well as press
release documents.
Vaccine efficacy and SARS-CoV-2 variants
A review of peer-reviewed publications was performed
to evaluate vaccine efficacy in relation to emergent
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Figure 1. Vaccines that reached phase III of clinical development.

Figure 2. Phase III vaccines categorized by technology.
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SARS-CoV-2 variants.

Results
Vaccines that reached phase III of clinical development
We identified 10 vaccines that reached phase III of clinical development. The classification of these 10 vaccines
vaccines according to phase III clinical trial status—
completed or ongoing—and availability of clinical trial
data are depicted in Figure 1.
Vaccine Technology
The technology used in the development of these 10
vaccines is depicted in Figure 2. Four vaccines used a
protein-based technology, and six vaccines used genebased technology.
Vaccine phase III clinical trial data
Four vaccines have completed phase III clinical trials
with data available in peer-reviewed journals. Our review of the data from these clinical trials in relation
to vaccine efficacy, number of trial participants, number of cases of COVID-19, and location of trial sites is
described in Table 1.[2–7] We identified three vaccines
with phase III clinical trial data from press release documents. The review of the available data for these vaccines is described in Table 2.[8–12]
Vaccine safety data
Some recipients of the vaccines under discussion have
reported mild to moderate adverse events. Local adverse events include pain at injection site, erythema,
pruritus and lymphadenopathy. Systemic adverse
events include fatigue, headache, fever, chills, nausea and vomiting. The Pfizer vaccine was associated with four cases of severe adverse events, including shoulder injury related to vaccine administration,
right axillary lymphadenopathy, paroxysmal ventricular arrhythmia, and right leg paresthesia.[3] Initially,
three cases of transverse myelitis (TM) and one case of
multiple sclerosis (MS) were associated with OxfordAstraZeneca vaccine, in response to which, the study
was placed on temporary hold for careful independent
review of each case.[4] It was determined that only 1
case of TM in the vaccine group was a vaccine-related
adverse event, while the remaining 2 cases of TM—one
in the vaccine group, the other in placebo group—were
unrelated to the vaccine.[4] Further independent investigation revealed that the patient in the vaccine group
who developed MS 10 days after receiving the first dose
had pre-existing, underlying, unrecognized MS; thus,
this case was also found to be unrelated to the vaccine.[4]
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study, two from the vaccine group and four from the
placebo group. However, the investigators concluded
that these deaths were not related to the vaccine or to
the placebo.[3] Gamaleya investigators reported three
deaths during the study, but none of these was reported
to be associated with the vaccine.[7] Johnson & Johnson
also reported three deaths that were not related to the
study.[8] Oxford-AstraZeneca reported five deaths, one
in the vaccine group and four in the placebo group.[4]
The death in the vaccine group was deemed unrelated
to the vaccine or to COVID-19, while in the placebo
group, there was one death due to severe COVID-19
leading to hospitalization 21 days after the first placebo
dose. The remaining three deaths in the placebo group
were unrelated to COVID-19 or to the vaccine.[4]
Vaccine efficacy and SARS-CoV-2 variants
Data on the potential efficacy of four vaccines against
new SARS-CoV-2 variants, as well as the origins of the
variants and the locations of their mutations, are described in Table 3.[8–10, 13–17] There are currently no
available data on the impact of the new COVID-19 variants on the severity of the disease, but the UK variant (B.1.1.7) and Brazil variant (P.1) have been found
to be more transmissible than the original SARS-CoV2 virus.[13] In a recent study, the Pfizer/BioNTech
vaccine demonstrated poor efficacy against the South
Africa variant (B.1.351).[18]

Discussion
Here, we reviewed the available data on the 10 vaccines that have—as of March 1, 2021—reached phase
III of the clinical development process. Data from peerreviewed publications are available for only four vaccines. The existing evidence concerning vaccine efficacy and safety is encouraging, but we still do not have
data on vaccine effectiveness and possible long-term
complications. As more vaccines come into the market, it will be important to define which vaccines will
be the most effective in preventing COVID-19, as well
as achieving herd immunity.
The existing data on vaccine efficacy against the emerging SARS-CoV-2 variants are very limited. Only four
vaccines (Pfizer/BioNTech, Novavax, Johnson & Johnson, and Bharat Biotech) have demonstrated efficacy
against these variants; in the cases of Pfizer/BioNTech
and Novavax, these effects have only been documented
in vitro. No data are available on the efficacy of any
vaccine against the California variant (CAL.20C). Future research should appraise COVID-19 vaccines on
the basis of variant coverage. With an increasingly
broad range of vaccines available, the potential risks
and benefits of combining different vaccines also require study.

Pfizer/BioNTech reported six deaths during their
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Table 1. Vaccines with peer-reviewed data.
Vaccine

Participants

Type
Enrolled

Vaccine

Placebo

COVID-19
Cases

Efficacy (95% CI)

Phase III Trial Site

No. of doses
(days apart)

Mod-NIH

RNA

30,420

15,210

15,210

196

94.1 (89.3–96.8)

USA

2 (28)

Pfi-BNT

RNA

43,448

21,720

21,728

170

94.6 (89.9–97.3)

USA, Germany, Turkey,
Africa, Brazil, Argentina

South

2 (21)

Oxf-Ast

Viral vector

23,848

12,082

11,766

131

70.4 (54.8–80.6)

UK, South Africa, Brazil

2 (28)

Gamaleya

Viral vector

21,977

16,501

5,476

78

91.6 (85.6–95.2)

Russia

2 (21)

MOD-NIH: mRNA-1273, developed by Moderna and the National Institutes of Health.[2]
Pfi-BNT: BNT162b2, developed by Pfizer and BioNTech.[3]
Oxf-Ast: Covishield/ChAdOx1 nCoV-19 (AZD1222), developed by Oxford University and AstraZeneca.[4, 5]
Gamaleya: Sputnik V/Gam-COVID-Vac, developed by the Gamaleya Research Institute.[6, 7]

Table 2. Vaccines with press release data.
Vaccine

Participants

Type

COVID-19
Cases

Efficacy (95% CI)

Phase III Trial Site

No. of doses

USA, Argentina,
Brazil, Chile,
Colombia, Mexico,
Peru, South Africa

1

Enrolled

Vaccine

Placebo

44,325

19,866

NA

469

66% (NA)

J&J

Viral vector

Recombinant spike
protein nanoparticle

15,000

NA

NA

62 (6:56)†

89.3% (75.2–95.4)

Nov-HHS

4,400∗

NA

NA

44 (15:29)†

60% (19.9–80.1)

South Africa

16,000

NA

NA

NA

NA

USA, Mexico

BB-NIV

Whole-virion inactivated

25,800

NA

NA

NA

NA

India

UK
2

2

J & J: Ad26.COV2-S, developed by Johnson & Johnson.[8, 9]
Nov-HHS: NVX-CoV2373, developed by Novavax and the Department of Health and Human Services.[10–11]
BB-NIV: Covaxin/BBV152, developed by Bharat Biotech and the National Institute of Virology.[12]
∗
Phase 2b. † Total (vaccine:placebo)

Table 3. SARS-CoV-2 variants.

∗

Name

Origin

Location of Mutations

First Reported

First Reported (US)

B.1.1.7 [13]

UK

Mutation in RBD* of spike
protein at position 501:
amino acid asparagine (N)
replaced with tyrosine (Y).†
P618H replacement on the
spike proteins.
Deletion at positions 69 and
70 of spike protein.

UK, September 2020

December 2020

Pfizer/BioNTech (in vitro
studies) [14]
Novavax
(NVX-CoV2373)
89.3% efficacy [10]
Covaxin/BBV152
Bharat
Biotech (in vitro studies) [15]

B.1.351 [13]

South Africa

Eight lineage-defining mutations in the spike protein
Spike protein,
including
K417N, E484K, N501Y

South Africa, October 2020

January 2021

Pfizer/BioNTech (in vitro
studies) [14]
Janssen (Phase III trial, 95%
S.A. population) [8, 9]
Novavax
(NVX-CoV2373)
60% efficacy [10]
Moderna (mRNA-1273) [17]

P.1 [13]

Brazil

17 unique mutations, including 3 in RBD of spike protein

Japan, January 2021

January 2021

Janssen [8, 9]
Novavax
(NVX-CoV2373)
[10]

CAL.20C [16]

USA (Southern CA)

Cluster 20C consists of 5
mutations: ORF1a: I4205V,
ORF1b: D1183Y, S: S13I;
W152C; L452R (S13I and
W152C in the N-terminal domain, and L452R in RBD)

Los Angeles (CA), July 2020

July 2020

Receptor binding domain

†

Vaccine Effectiveness

Unknown

The shorthand for this mutation is N501Y
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